204696-52-6

Usage

Uses

1. Used in Pharmaceutical Industry:
[(R)-(R,S)]-[5-[[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]amino]-6-oxo-6-[4-(4-pyridinyl)-1-piperazinyl]hexyl]-carbamic acid 1,1-dimethylethyl ester is used as a potential therapeutic agent for various medical conditions due to its complex structure and the presence of multiple bioactive moieties.
2. Used in Chemical Research:
[(R)-(R,S)]-[5-[[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]amino]-6-oxo-6-[4-(4-pyridinyl)-1-piperazinyl]hexyl]-carbamic acid 1,1-dimethylethyl ester is also used as a subject of study in chemical research to explore its reactivity, stability, and potential for the development of new drugs or materials.
3. Used in Material Science:
Given its unique structure, [(R)-(R,S)]-[5-[[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]amino]-6-oxo-6-[4-(4-pyridinyl)-1-piperazinyl]hexyl]-carbamic acid 1,1-dimethylethyl ester may be utilized in the development of new materials with specific properties for various applications in material science.

Upstream product

• 204692-66-0 1-[N⁶-(1,1-dimethylethoxycarbonyl)-L-lysyl]-4-(4-pyridinyl)piperazine 
• 862805-23-0 3,5-dibromo-N-{[4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidin-1-yl]carbonyl}-D-tyrosine 
• 79098-75-2 3-piperidin-4-yl-3,4-dihydro-1H-quinazoline-2-one 
• 173383-29-4 3,5-dibromo-D-tyrosine methyl ester 

Relevant academic research and scientific papers

Serendipitous oxidation product of BIBN4096BS: A potent CGRP receptor antagonist

An oxidation product (5) formed during the synthesis of BIBN-4096BS (1) was found to be a potent CGRP antagonist (IC50 = 0.11 nM). While 5 was found to be ten-fold less potent than 1, another analog 8 with lower molecular weight containing the

Serendipitous oxidation product of BIBN4096BS: A potent CGRP receptor antagonist

An oxidation product (5) formed during the synthesis of BIBN-4096BS (1) was found to be a potent CGRP antagonist (IC50 = 0.11 nM). While 5 was found to be ten-fold less potent than 1, another analog 8 with lower molecular weight containing the

Process for preparing 1- [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine

The present application relates to a process for preparing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine of formula by means of which this compound can be prepared in large amounts, in high yields and with high purity.

METHOD FOR THE PRODUCTION OF 1-[N2-[3,5-DIBROMO-N-[[4-(3,4-DIHYDRO-2(1H)-OXOQUINAZOLINE-3-YL)-1-PIPERIDINYL]CARBONYL]-D-TYROSYL]-L-LYSYL]-4-(4-PYRIDINYL)-PIPERAZINE

The invention relates to a method for producing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazine of formula (I). The disclosed method allows said compound to be produced in great quantities, at great yields, and at a high degree of purity.